Efficacy Evaluation of Shen Cao Gan Jiang Tang on Mild and Moderate COVID-19 Patients

This is an interventional treatment trial for COVID-19 Respiratory Infection Read More

Inclusion Criteria:

• From full 18 to 64 years old;
• The patient was diagnosed with SARS-CoV-2 infection by RT-PCR confirmation (+) and CT < 30.
• Patients classified as mild (acute upper respiratory tract infection): patients infected with SARS-CoV-2 early in the first 5 days from the time of having one of the non-specific clinical symptoms such as fever, cough dry, sore throat, stuffy nose, fatigue, headache, muscle pain, decreased taste, decreased sense of smell. And there are no signs of pneumonia or hypoxia, respiratory rate ≤ 20 times/min, Saturation of Peripheral Oxygen (SpO2) ≥ 96% when breathing air.
• Patients classified as moderate (Pneumonia): patients infected with SARS-CoV-2 in the first 10 days from the time of having one of the non-specific clinical symptoms, showing signs of pneumonia (fever, cough, dyspnea, tachypnea >20 breaths/min) and no signs of severe pneumonia, Saturation of Peripheral Oxygen (SpO2) ≥ 93% when breathing air.
• Inpatient treatment
• Subjects do not use any other medicines with herbal ingredients for underlying conditions or any other purposes;
• Voluntary participation in the study by signing an informed consent
• Patients who have not been vaccinated or have just received 1 dose of COVID-19 vaccine

Exclusion Criteria:

• Severe or critical COVID-19 based on the COVID-19 severity scale of Vietnam Ministry of Health;
• Chronic obstructive pulmonary disease, kidney failure requiring dialysis or creatinine ≥ 2.0mg/dl through medical history; parenteral or parenteral nutrition, uncontrolled type 2 diabetes (HbA1c > 7%), uncontrolled hypertension (value > 160/100 mmHg), uncontrolled coronary artery disease (new/currently established) requires medication adjustment), heart failure, neurological disease (eg, acute stroke, polyneuritis within 1 month) or mental illness, active tuberculosis, active autoimmune disease;
• Have a chronically weakened immune system (AIDS, cancer, undergoing chemotherapy-radiotherapy in the past six months, immunosuppressive disease);
• Taking immunosuppressive drugs (e.g., anti-rejection treatment after organ transplant or blood stem cell transplant);
• Allergic to products that contain ginseng;
• Pregnant or lactating women;
• Already participating in another clinical trial;
• The patient has received 2 doses of COVID-19 vaccine.